Regeneron Pharmaceuticals, Inc.
REGN
$718.16
-$26.67-3.58%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -31.55% | -6.40% | 98.38% | -37.74% | 15.06% |
| Total Depreciation and Amortization | 3.86% | 0.83% | 5.78% | 0.97% | 7.21% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 384.61% | 63.10% | -223.15% | 294.16% | -162.82% |
| Change in Net Operating Assets | -35.21% | 92.97% | -306.24% | 817.43% | 68.07% |
| Cash from Operations | -2.20% | 264.75% | -76.60% | 38.80% | -2.21% |
| Capital Expenditure | 17.49% | -34.02% | -34.80% | 46.74% | -42.84% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -- | -- | -- |
| Cash Acquisitions | -- | 100.00% | -- | -- | 92.56% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 268.93% | 15.14% | 74.77% | -921.80% | 170.21% |
| Cash from Investing | 161.04% | -3.09% | 66.97% | -2,448.49% | 86.66% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -64.31% | -41.80% | -35.85% | 126.61% | 12.06% |
| Repurchase of Common Stock | -43.39% | 6.60% | -44.20% | 15.00% | -10.53% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -- | -- | -- | -- |
| Cash from Financing | -79.10% | -32.61% | -1,115.07% | 110.56% | -9.53% |
| Foreign Exchange rate Adjustments | -187.50% | 366.67% | 40.00% | -350.00% | 200.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 470.81% | 112.27% | -432.50% | -122.16% | 174.39% |
